Pulnovo Medical Announces Results of the PADN-HF-PH Trial at ESC Congress 2026, Simultaneously Published in The New England Journal of Medicine (NEJM)

In 264 PH-LHD patients, the therapy showed a 51% reduction in the risk of clinical worsening and a 35.5% decrease in recurrent clinical events, alongside sustained concurrent improvements in functional capacity. These multi-dimensional clinical benefits strengthen the case for the treatment’s efficacy and could support improved investor outlook.